

REMARKS

Entry of this amendment and reconsideration of this application, as amended, are respectfully requested.

The undersigned gratefully acknowledges the courtesies extended by the Examiner during the personal interview of August 6, 2007. The undersigned agrees with the summary of the interview set forth in the Interview Summary Report prepared by the Examiner.

It is respectfully submitted that the amendments made herein are not believed to introduce any new matter for reasons discussed in more detail below.

It is respectfully submitted that the 35 U.S.C. §102(b) rejection and the obviousness-type double patenting rejection of claims set forth in the office action do not apply to the amended and new claim. It is also submitted that the 35 U.S.C. §112, second paragraph, rejection of the claims does not apply to the amended and new claim.

Claims 41-51 were rejected under 35 U.S.C. §112, first paragraph for allegedly not being enabled. To the extent this rejection may apply to the presently pending claims, Applicants respectfully submit that the amendments to the specification incorporating SEQ ID NO:1 overcomes this rejection. This amendment finds support because the Calbiochem molecule is clearly identified as "PKCα pseudosubstrate myristoylated" e.g., in Example 22 and all publications, patents, patent applications and sequences identified by their name and/or database accession numbers mentioned in the specification were incorporated by reference (See the last paragraph of the application). Therefore, no new matter is believed to have been added.

Furthermore, as set forth in the accompanying declaration of the inventor, this molecule is well known to one of skill in the art and would be clearly and immediately recognized by the skilled artisan as such because there are no other such inhibitors on the Calbiochem website, nor, as set forth in the declaration, were there any other such molecules available on the Calbiochem website at the time the application was filed.

Additionally, and also as set forth in the declaration, the inventor's internal reference identifies the molecule as HO/02, which is in the original specification, and the declaration provides evidence showing that this molecule was what was used in the experiments.

Clearly, one of skill in the art would clearly, immediately and unambiguously recognize that Calbiochem molecule set forth in the application as originally filed is the molecule of SEQ ID NO:1.


In view of the foregoing, it is respectfully submitted that the 35 U.S.C. §112, first paragraph, rejection should be withdrawn.

Since all issues raised in the office action are believed to have been resolved, allowance is respectfully requested.

The Commissioner is authorized to charge any additional fees due to deposit account no. 50-0624.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 
James R. Crawford
Reg. No. 39,155

666 Fifth Avenue
New York, NY 10103
(212) 318-3148

Encls.-Declaration of Inventor
Letter re Sequence Listing
Disk with Sequence Listing